Literature DB >> 18973096

Immunologic responses to therapeutic biologic agents.

R T Purcell1, R F Lockey.   

Abstract

Recombinant protein technology and the subsequent development of biologic agents for pharmacotherapy have greatly improved the treatment of a wide variety of diseases in humans. These products are subject to reactions not previously seen in other drug classes. Additionally, subtle alteration in the manufacture or administration of a biologic agent may cause reactions in subjects who previously tolerated it. This review highlights the unique immunologic reactions that are associated with the more commonly used biologic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973096

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  14 in total

1.  Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response.

Authors:  Rossella Talotta; Angela Berzi; Fabiola Atzeni; Alberto Batticciotto; Mario Clerici; Piercarlo Sarzi-Puttini; Daria Trabattoni
Journal:  J Clin Immunol       Date:  2015-08-14       Impact factor: 8.317

2.  Biosimilars: Implications for health-system pharmacists.

Authors:  Steven D Lucio; James G Stevenson; James M Hoffman
Journal:  Am J Health Syst Pharm       Date:  2013-11-15       Impact factor: 2.637

3.  Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.

Authors:  Lívia Moreira Genaro; Luís Eduardo Miani Gomes; Ana Paula Menezes de Freitas Franceschini; Hugo Dugolin Ceccato; Rafael Nascimento de Jesus; Amanda Pereira Lima; Cristiane Kibune Nagasako; João José Fagundes; Maria de Lourdes Setsuko Ayrizono; Raquel Franco Leal
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

4.  Lebrikizumab in the personalized management of asthma.

Authors:  Neil C Thomson; Manish Patel; Andrew D Smith
Journal:  Biologics       Date:  2012-09-14

5.  Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.

Authors:  Alejandro Huerta-Saquero; Zahaed Evangelista-Martínez; Angélica Moreno-Enriquez; Ernesto Perez-Rueda
Journal:  Bioengineered       Date:  2012-08-16       Impact factor: 3.269

Review 6.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

Review 7.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

Authors:  William R Strohl
Journal:  BioDrugs       Date:  2015-08       Impact factor: 5.807

8.  B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.

Authors:  Arne Homann; Niels Röckendorf; Arno Kromminga; Andreas Frey; Uta Jappe
Journal:  J Transl Med       Date:  2015-10-29       Impact factor: 5.531

Review 9.  Hypersensitivity and Immune-related Adverse Events in Biologic Therapy.

Authors:  Jamie L Waldron; Stephen A Schworer; Mildred Kwan
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-28       Impact factor: 8.667

10.  Pharmacovigilance Considerations for Biosimilars in the USA.

Authors:  Gustavo Grampp; Thomas Felix
Journal:  BioDrugs       Date:  2015-10       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.